A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21). Jung HA, Kim M, Kim HS, Kim JH, et al. J Thorac Oncol 2023;18:223-231.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jung HA, Kim M, Kim HS, Kim JH, et al. A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21). J Thorac Oncol 2023;18:223-231.
PMID: 36307042